Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new opportunities to expand access to their medicines through PAPs.

Former head of the Covid Vaccine Task Force Dr Clive Dix accused ministers of a 'fatuous argument', claiming the country is ...

Metro Mayor Steve Rotheram has said he is hoping to restart talks with AstraZeneca after it scrapped plans to invest £450m in ...

The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Pharmaceutical company AstraZeneca has cancelled a planned 450 million-pound investment in a vaccine manufacturing plant in ...

AstraZeneca has scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Liverpool, blaming a reduction in government support. The pharmaceutical giant has announced its decision ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

-- AstraZeneca has shelved a plan to build a vaccine manufacturing plant in Speke, near Liverpool, valued at 450 million pounds ($558.7 million), after months of talks with British government ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.